ARTICLE | Company News
Clarient, Minerva Biotechnologies deal
December 7, 2009 8:00 AM UTC
Clarient received an exclusive, worldwide license to develop and commercialize a pharmacogenetic test that uses Minerva's MUC1*, an altered form of mucin 1 ( MUC1, CD227), biomarker. The companies w...